MannKind and Sanofi Complete Afrezza Collaboration Deal Print
By Josh Gee   
Friday, 26 September 2014 18:59
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 26, 2014.
MannKind Corporation ($MNKD) has been in search of a suitable partner ever since the FDA cleared Afrezza inhalation powder for the improvement of glycemic control in adults suffering from diabetes mellitus in Jun 2014. In Aug 2014, MannKind finally ended its search when it announced a worldwide agreement with Sanofi (SNY) on Afrezza (read: MannKind Enters into a Global Deal with Sanofi for Afrezza).

Earlier in the week, MannKind announced that it has completed the above deal with Sanofi. The exclusive collaboration and licensing agreement between MannKind and Sanofi is for the development and commercialization of Afrezza.

As per the deal, Sanofi is responsible for commercial, regulatory and development activities pertaining to Afrezza across the globe. The companies also inked a supply agreement according to which MannKind will manufacture Afrezza at its manufacturing facility in Danbury, CT. Shares of MannKind had gained significantly after striking the partnership deal with Sanofi.

The completion of the deal follows the U.S. Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act. It also follows the completion of documentation for the $175 million loan facility provided by Sanofi related to the agreement. MannKind will receive a $150 million upfront payment shortly.

Also Friday:


Advaxis, Inc. (Nasdaq:ADXS)
, a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary Lm-LLO immunotherapy, was featured on Fox News Philadelphia in a segment focused on how dogs battling osteosarcoma (bone cancer) can help lead research for treating osteosarcoma and breast cancer in humans.

Applied Genetic Technologies Corporation (Nasdaq:AGTC)
, a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the quarter and fiscal year ended June 30, 2014.

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA)
today announced a number of changes to management and its board of directors that will become effective October 1, 2014.

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA)
today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent corporate developments.

Cannabis Kinetics Corp. (OTCQB: CANK
, an emerging fully integrated cannabis management company, is pleased to announce that it has entered into an Exclusive Distribution Agreement with Ivory Coco International, LLC, a Colorado-based importer and supplier of Coco Coir, an all-natural soil additive utilized by indoor and outdoor gardening operations.

GlycoMimetics, Inc. (Nasdaq:GLYC)
announced today that it has been informed by Pfizer (NYSE:PFE), the company responsible for ongoing clinical development of rivipansel, that initiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will be significantly delayed due to a manufacturing development issue impacting formulated drug supply.

Immunomedics, Inc., (Nasdaq:IMMU)
today announced the publication in Molecular Cancer Therapeutics1 of an article describing the development of a bispecific antibody, (E1)-3s, that redirects human T cells to certain solid cancers, and its combination with interferon-alpha (IFNα).

Pain Therapeutics, Inc. (Nasdaq:PTIE)
, a drug development company, today announced it has expanded its pipeline with the addition of FENROCK, an early-stage drug candidate. FENROCK is a transdermal (skin) patch that contains fentanyl, a strong opioid drug typically used to manage severe cancer pain.

Prosensa Holding N.V. (NASDAQ: RNA)
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has extended its comprehensive program of re-dosing of drisapersen in  patients with Duchenne muscular dystrophy (DMD) into Europe, with the PRO051-02/DMD114673 sites re-opening, beginning with Belgium.

Repros Therapeutics Inc.® (Nasdaq:RPRX)
today reported it has been granted a Type B Pre-NDA meeting with the FDA in the first half of November.

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT)
today announced the launch of GLYDO™ (lidocaine HCI jelly USP, 2%), Sagent's new branded drug offering.

Tauriga Sciences, Inc. (OTCQB:TAUG)
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced the restructuring of its acquisition of Honeywood LLC into a License and Supply Agreement which provides Tauriga access to the Doc Green's topical cannabis cream and future products., Inc. (PINKSHEETS: SEEK)
, an emerging leader in the Vertical and Local search space, today announced that it will report 2014 Q3 operating results after the market close on October 14th, 2014.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus